Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vignesh T Packiam

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
The Journal of Urology|March 20, 2020
Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder CancerVidit Sharma, Kevin M Wymer, Bijan J Borah, et al.
European Urology Oncology|July 19, 2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder CancerWei Shen Tan, Ian M McElree, Facundo Davaro, et al.
Archives of Pathology & Laboratory Medicine|June 14, 2022
Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical CystectomySvetlana Avulova, Tarik Benidir, John C Cheville, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 12, 2021
Partial versus radical nephrectomy in clinical T2 renal massesDane E Klett, Matvey Tsivian, Vignesh T Packiam, et al.
The Prostate|July 4, 2017
Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trialHaitao Chen, Rong Na, Vignesh T Packiam, et al.
Urologic Oncology|February 1, 2025
Rethinking the definition of stage III disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive diseaseBenjamin J Lichtbroun, Helen Gao, Kevin Chua, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
BJU International|November 3, 2025
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancerAshley C Rhodes, Kaitlyn A McClintic, Emily Witt, et al.
Urology|September 9, 2023
Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary SeriesReza Nabavizadeh, Rodrigo Rodrigues Pessoa, Mihai G Dumbrava, et al.
European Urology Focus|July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)Max Kates, Xiangying Chu, Noah Hahn, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
The Journal of Urology|March 20, 2020
Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder CancerVidit Sharma, Kevin M Wymer, Bijan J Borah, et al.
European Urology Oncology|July 19, 2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder CancerWei Shen Tan, Ian M McElree, Facundo Davaro, et al.
Archives of Pathology & Laboratory Medicine|June 14, 2022
Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical CystectomySvetlana Avulova, Tarik Benidir, John C Cheville, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 12, 2021
Partial versus radical nephrectomy in clinical T2 renal massesDane E Klett, Matvey Tsivian, Vignesh T Packiam, et al.
The Prostate|July 4, 2017
Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trialHaitao Chen, Rong Na, Vignesh T Packiam, et al.
Urologic Oncology|February 1, 2025
Rethinking the definition of stage III disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive diseaseBenjamin J Lichtbroun, Helen Gao, Kevin Chua, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
BJU International|November 3, 2025
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancerAshley C Rhodes, Kaitlyn A McClintic, Emily Witt, et al.
Urology|September 9, 2023
Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary SeriesReza Nabavizadeh, Rodrigo Rodrigues Pessoa, Mihai G Dumbrava, et al.
European Urology Focus|July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)Max Kates, Xiangying Chu, Noah Hahn, et al.
Pageof 14